2026 Q1 -tulosraportti
76 päivää sitten
‧43 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenNOT directly related to Curasight! - but an interesting and potential application of radiopharma for use in immunotherapy: https://nuclionews.com/article/can-radiopharma-make-immunotherapy-work-better
Don't understand much of it, so I got AI to reproduce the 5 most important points. I didn't get much wiser from that either, but it sounds exciting. Especially because I also have a share (Ion Beam Applications) that has a stake in an "Actinium-225" company (startup). ----AI---- >Radiopharmaceuticals can restart the body's own immune system against cancer by changing the tumor's microenvironment, which creates entirely new possibilities for combination treatment with immunotherapy. From cell killing to immunomodulation: Radiopharmaceuticals do not merely kill cancer cells directly; they also trigger "immunogenic cell death," which releases antigens and transforms immunologically "cold" (invisible) tumors into "hot" tumors that the immune system can recognize. Interaction with checkpoint inhibitors: Targeted radiation can act as a catalyst for immunotherapy (such as PD-1/PD-L1 inhibitors). This makes the treatment more effective in cancer types where immunotherapy alone normally has limited effect. Targeting immunosuppressive cells: New approaches utilize alpha emitters (e.g., Actinium-225) to remove the specific immunosuppressive cells (MDSCs) in the tumor environment that otherwise block the body's own immune response. Complex dosing and timing: The highest radiation dose does not necessarily yield the best result. Too strong radiation can kill the beneficial T-cells, so success depends on finding the right balance between cell killing and preservation of the immune response. Great strategic potential for the pharma industry: Large pharmaceutical companies are building patents and clinical programs because radiopharmaceuticals can act as an "enabler" that makes existing billion-dollar preparations within immunotherapy effective in many more patients.
·2 päivää sittenI just tried to get AI to thoroughly analyze and summarize what the latest press release actually means, Pros/Cons in the short and long term. I think it came back with a pretty good answer, in a language everyone can understand. AI wrote this back to me: The press release means in practice that Curasight is optimizing and expanding their ongoing clinical Phase I study (uTREAT®) against aggressive brain cancer (glioblastoma). Overall, this is positive, as it can make a future treatment easier to approve and use, but it also entails a delay of the study in the short term. ## What changes in practice? * No artificial opening of the blood-brain barrier: New patients will not have the substance mannitol injected to open the barrier to the brain. * Full anesthesia introduced: Patients are placed under general anesthesia during the procedure to ensure that doctors can target precisely under optimal working conditions. * More patients included in the study: The number of participants is increased, so that at least 6 patients are included in the new group, which is tested without barrier opening. ## Why is this GOOD? * Simpler treatment: If uTREAT® works without having to penetrate the blood-brain barrier with mannitol, the treatment will be much simpler to perform in the future. * Stronger scientific data: By comparing patients who received mannitol with patients who did not, Curasight gains valuable knowledge to design the next and crucial phases of their studies. * Broader application: A simpler process means that the treatment can potentially be rolled out to many more hospitals and patients globally. ## Why is this BAD (or a disadvantage)? * Time delay: Because more patients need to be recruited for the study, Curasight directly states that it will take longer to complete this phase. * Awaiting approval: The changes must first be approved by the relevant authorities and ethical committees before they can be rolled out. ## Conclusion This is a classic expression of due diligence in the biotech industry. The company uses the experience it has already gathered in the study to make the final product more valuable and easier to commercialize. For investors and patients, the scientific upgrade is positive, even if one must arm oneself with patience regarding the timeline. Are you interested in knowing more about how this change might affect Curasight's overall pipeline, or would you like a more detailed explanation of what uTREAT technology precisely does to cancer cells?ENSkilda just had a buyer who bought approx. 10k. shares, i.e., for approx 150000 dkk......= the share rose around 6% That's what I mean by the price will quickly rise, if some new ones want in, or maybe some want back.....- ·2 päivää sittenOne reflection on Curium's acquisition (Lantheus + Abscint): "𝗖𝘂𝗿𝗶𝘂𝗺 𝗶𝘀 𝗻𝗼𝘁 𝗮𝗹𝗼𝗻𝗲. The same strategic shift is playing out across radiopharmaceuticals. Bristol Myers Squibb acquired RayzeBio. AstraZeneca acquired Fusion Pharmaceuticals. Eli Lilly acquired POINT Biopharma. Novartis acquired Mariana Oncology. While each transaction had its own strategic rationale, they point in the same direction: companies are increasingly investing 𝗻𝗼𝘁 𝗼𝗻𝗹𝘆 𝗶𝗻 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀, 𝗯𝘂𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 required to repeatedly discover, develop, manufacture, commercialize, and deliver radiopharmaceuticals at scale." https://www.linkedin.com/posts/leilasafavi_curiums-agreement-last-week-to-acquire-lantheus-share-7492675732456968192-VdEo/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAdDk4B7F9UTNBBVZkrUAyD6jiiomxO1ao Let's hope Curasight will fit into such strategic considerations ;)Why doesn't Curium just buy Curasight? Can't they afford it? They of all people know that uTrace works....
- ·3 päivää sittenI wonder what they paid (phase 2b stage)? https://www.curiumpharma.com/2026/08/10/curium-acquires-abscint/Just for fun, I asked Google for its guess. So total AI!! If I were to make an educated guess on the price for Curium's acquisition of Abscint SA, my estimate would be between 30 and 75 million euros (approx. 225 - 560 million DKK) in total transaction value, including the so-called "milestone" payments. Here are the most important factors and assumptions on which I base this guess: 📊 Rationale for the estimateEarly stage with high risk: Abscint's primary asset, ABS-011, is in Phase 2b testing. Because the product is not yet approved for sale, the buyer rarely pays large billion amounts up-front. The risk that the product fails in the final tests is still present. Previous financing as a benchmark: Abscint raised a financing round of 3 million euros in 2023 to cover the Phase 2 studies. A young biotech company at this stage is typically acquired for a value 10 to 20 times greater than their latest capital raising. Typical deal structure: In this type of medical acquisition, Curium will likely only pay a smaller portion in cash here and now (e.g., 10-20 million euros). The rest of the amount will only be paid out if ABS-011 achieves success in the Phase 3 tests and is finally approved by the authorities.
·3 päivää sittenIt seems that we are gradually staying at this level, or what are people's impressions?
Yes, it should be around this level. With current market cap. of approx. 700 mill I can quite easily imagine it quickly coming back to around 20 - 22 kr. Per Share.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
76 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenNOT directly related to Curasight! - but an interesting and potential application of radiopharma for use in immunotherapy: https://nuclionews.com/article/can-radiopharma-make-immunotherapy-work-betterDon't understand much of it, so I got AI to reproduce the 5 most important points. I didn't get much wiser from that either, but it sounds exciting. Especially because I also have a share (Ion Beam Applications) that has a stake in an "Actinium-225" company (startup). ----AI---- >Radiopharmaceuticals can restart the body's own immune system against cancer by changing the tumor's microenvironment, which creates entirely new possibilities for combination treatment with immunotherapy. From cell killing to immunomodulation: Radiopharmaceuticals do not merely kill cancer cells directly; they also trigger "immunogenic cell death," which releases antigens and transforms immunologically "cold" (invisible) tumors into "hot" tumors that the immune system can recognize. Interaction with checkpoint inhibitors: Targeted radiation can act as a catalyst for immunotherapy (such as PD-1/PD-L1 inhibitors). This makes the treatment more effective in cancer types where immunotherapy alone normally has limited effect. Targeting immunosuppressive cells: New approaches utilize alpha emitters (e.g., Actinium-225) to remove the specific immunosuppressive cells (MDSCs) in the tumor environment that otherwise block the body's own immune response. Complex dosing and timing: The highest radiation dose does not necessarily yield the best result. Too strong radiation can kill the beneficial T-cells, so success depends on finding the right balance between cell killing and preservation of the immune response. Great strategic potential for the pharma industry: Large pharmaceutical companies are building patents and clinical programs because radiopharmaceuticals can act as an "enabler" that makes existing billion-dollar preparations within immunotherapy effective in many more patients.
- ·2 päivää sittenI just tried to get AI to thoroughly analyze and summarize what the latest press release actually means, Pros/Cons in the short and long term. I think it came back with a pretty good answer, in a language everyone can understand. AI wrote this back to me: The press release means in practice that Curasight is optimizing and expanding their ongoing clinical Phase I study (uTREAT®) against aggressive brain cancer (glioblastoma). Overall, this is positive, as it can make a future treatment easier to approve and use, but it also entails a delay of the study in the short term. ## What changes in practice? * No artificial opening of the blood-brain barrier: New patients will not have the substance mannitol injected to open the barrier to the brain. * Full anesthesia introduced: Patients are placed under general anesthesia during the procedure to ensure that doctors can target precisely under optimal working conditions. * More patients included in the study: The number of participants is increased, so that at least 6 patients are included in the new group, which is tested without barrier opening. ## Why is this GOOD? * Simpler treatment: If uTREAT® works without having to penetrate the blood-brain barrier with mannitol, the treatment will be much simpler to perform in the future. * Stronger scientific data: By comparing patients who received mannitol with patients who did not, Curasight gains valuable knowledge to design the next and crucial phases of their studies. * Broader application: A simpler process means that the treatment can potentially be rolled out to many more hospitals and patients globally. ## Why is this BAD (or a disadvantage)? * Time delay: Because more patients need to be recruited for the study, Curasight directly states that it will take longer to complete this phase. * Awaiting approval: The changes must first be approved by the relevant authorities and ethical committees before they can be rolled out. ## Conclusion This is a classic expression of due diligence in the biotech industry. The company uses the experience it has already gathered in the study to make the final product more valuable and easier to commercialize. For investors and patients, the scientific upgrade is positive, even if one must arm oneself with patience regarding the timeline. Are you interested in knowing more about how this change might affect Curasight's overall pipeline, or would you like a more detailed explanation of what uTREAT technology precisely does to cancer cells?ENSkilda just had a buyer who bought approx. 10k. shares, i.e., for approx 150000 dkk......= the share rose around 6% That's what I mean by the price will quickly rise, if some new ones want in, or maybe some want back.....
- ·2 päivää sittenOne reflection on Curium's acquisition (Lantheus + Abscint): "𝗖𝘂𝗿𝗶𝘂𝗺 𝗶𝘀 𝗻𝗼𝘁 𝗮𝗹𝗼𝗻𝗲. The same strategic shift is playing out across radiopharmaceuticals. Bristol Myers Squibb acquired RayzeBio. AstraZeneca acquired Fusion Pharmaceuticals. Eli Lilly acquired POINT Biopharma. Novartis acquired Mariana Oncology. While each transaction had its own strategic rationale, they point in the same direction: companies are increasingly investing 𝗻𝗼𝘁 𝗼𝗻𝗹𝘆 𝗶𝗻 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀, 𝗯𝘂𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 required to repeatedly discover, develop, manufacture, commercialize, and deliver radiopharmaceuticals at scale." https://www.linkedin.com/posts/leilasafavi_curiums-agreement-last-week-to-acquire-lantheus-share-7492675732456968192-VdEo/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAdDk4B7F9UTNBBVZkrUAyD6jiiomxO1ao Let's hope Curasight will fit into such strategic considerations ;)Why doesn't Curium just buy Curasight? Can't they afford it? They of all people know that uTrace works....
- ·3 päivää sittenI wonder what they paid (phase 2b stage)? https://www.curiumpharma.com/2026/08/10/curium-acquires-abscint/Just for fun, I asked Google for its guess. So total AI!! If I were to make an educated guess on the price for Curium's acquisition of Abscint SA, my estimate would be between 30 and 75 million euros (approx. 225 - 560 million DKK) in total transaction value, including the so-called "milestone" payments. Here are the most important factors and assumptions on which I base this guess: 📊 Rationale for the estimateEarly stage with high risk: Abscint's primary asset, ABS-011, is in Phase 2b testing. Because the product is not yet approved for sale, the buyer rarely pays large billion amounts up-front. The risk that the product fails in the final tests is still present. Previous financing as a benchmark: Abscint raised a financing round of 3 million euros in 2023 to cover the Phase 2 studies. A young biotech company at this stage is typically acquired for a value 10 to 20 times greater than their latest capital raising. Typical deal structure: In this type of medical acquisition, Curium will likely only pay a smaller portion in cash here and now (e.g., 10-20 million euros). The rest of the amount will only be paid out if ABS-011 achieves success in the Phase 3 tests and is finally approved by the authorities.
- ·3 päivää sittenIt seems that we are gradually staying at this level, or what are people's impressions?Yes, it should be around this level. With current market cap. of approx. 700 mill I can quite easily imagine it quickly coming back to around 20 - 22 kr. Per Share.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
76 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenNOT directly related to Curasight! - but an interesting and potential application of radiopharma for use in immunotherapy: https://nuclionews.com/article/can-radiopharma-make-immunotherapy-work-betterDon't understand much of it, so I got AI to reproduce the 5 most important points. I didn't get much wiser from that either, but it sounds exciting. Especially because I also have a share (Ion Beam Applications) that has a stake in an "Actinium-225" company (startup). ----AI---- >Radiopharmaceuticals can restart the body's own immune system against cancer by changing the tumor's microenvironment, which creates entirely new possibilities for combination treatment with immunotherapy. From cell killing to immunomodulation: Radiopharmaceuticals do not merely kill cancer cells directly; they also trigger "immunogenic cell death," which releases antigens and transforms immunologically "cold" (invisible) tumors into "hot" tumors that the immune system can recognize. Interaction with checkpoint inhibitors: Targeted radiation can act as a catalyst for immunotherapy (such as PD-1/PD-L1 inhibitors). This makes the treatment more effective in cancer types where immunotherapy alone normally has limited effect. Targeting immunosuppressive cells: New approaches utilize alpha emitters (e.g., Actinium-225) to remove the specific immunosuppressive cells (MDSCs) in the tumor environment that otherwise block the body's own immune response. Complex dosing and timing: The highest radiation dose does not necessarily yield the best result. Too strong radiation can kill the beneficial T-cells, so success depends on finding the right balance between cell killing and preservation of the immune response. Great strategic potential for the pharma industry: Large pharmaceutical companies are building patents and clinical programs because radiopharmaceuticals can act as an "enabler" that makes existing billion-dollar preparations within immunotherapy effective in many more patients.
- ·2 päivää sittenI just tried to get AI to thoroughly analyze and summarize what the latest press release actually means, Pros/Cons in the short and long term. I think it came back with a pretty good answer, in a language everyone can understand. AI wrote this back to me: The press release means in practice that Curasight is optimizing and expanding their ongoing clinical Phase I study (uTREAT®) against aggressive brain cancer (glioblastoma). Overall, this is positive, as it can make a future treatment easier to approve and use, but it also entails a delay of the study in the short term. ## What changes in practice? * No artificial opening of the blood-brain barrier: New patients will not have the substance mannitol injected to open the barrier to the brain. * Full anesthesia introduced: Patients are placed under general anesthesia during the procedure to ensure that doctors can target precisely under optimal working conditions. * More patients included in the study: The number of participants is increased, so that at least 6 patients are included in the new group, which is tested without barrier opening. ## Why is this GOOD? * Simpler treatment: If uTREAT® works without having to penetrate the blood-brain barrier with mannitol, the treatment will be much simpler to perform in the future. * Stronger scientific data: By comparing patients who received mannitol with patients who did not, Curasight gains valuable knowledge to design the next and crucial phases of their studies. * Broader application: A simpler process means that the treatment can potentially be rolled out to many more hospitals and patients globally. ## Why is this BAD (or a disadvantage)? * Time delay: Because more patients need to be recruited for the study, Curasight directly states that it will take longer to complete this phase. * Awaiting approval: The changes must first be approved by the relevant authorities and ethical committees before they can be rolled out. ## Conclusion This is a classic expression of due diligence in the biotech industry. The company uses the experience it has already gathered in the study to make the final product more valuable and easier to commercialize. For investors and patients, the scientific upgrade is positive, even if one must arm oneself with patience regarding the timeline. Are you interested in knowing more about how this change might affect Curasight's overall pipeline, or would you like a more detailed explanation of what uTREAT technology precisely does to cancer cells?ENSkilda just had a buyer who bought approx. 10k. shares, i.e., for approx 150000 dkk......= the share rose around 6% That's what I mean by the price will quickly rise, if some new ones want in, or maybe some want back.....
- ·2 päivää sittenOne reflection on Curium's acquisition (Lantheus + Abscint): "𝗖𝘂𝗿𝗶𝘂𝗺 𝗶𝘀 𝗻𝗼𝘁 𝗮𝗹𝗼𝗻𝗲. The same strategic shift is playing out across radiopharmaceuticals. Bristol Myers Squibb acquired RayzeBio. AstraZeneca acquired Fusion Pharmaceuticals. Eli Lilly acquired POINT Biopharma. Novartis acquired Mariana Oncology. While each transaction had its own strategic rationale, they point in the same direction: companies are increasingly investing 𝗻𝗼𝘁 𝗼𝗻𝗹𝘆 𝗶𝗻 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀, 𝗯𝘂𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 required to repeatedly discover, develop, manufacture, commercialize, and deliver radiopharmaceuticals at scale." https://www.linkedin.com/posts/leilasafavi_curiums-agreement-last-week-to-acquire-lantheus-share-7492675732456968192-VdEo/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAdDk4B7F9UTNBBVZkrUAyD6jiiomxO1ao Let's hope Curasight will fit into such strategic considerations ;)Why doesn't Curium just buy Curasight? Can't they afford it? They of all people know that uTrace works....
- ·3 päivää sittenI wonder what they paid (phase 2b stage)? https://www.curiumpharma.com/2026/08/10/curium-acquires-abscint/Just for fun, I asked Google for its guess. So total AI!! If I were to make an educated guess on the price for Curium's acquisition of Abscint SA, my estimate would be between 30 and 75 million euros (approx. 225 - 560 million DKK) in total transaction value, including the so-called "milestone" payments. Here are the most important factors and assumptions on which I base this guess: 📊 Rationale for the estimateEarly stage with high risk: Abscint's primary asset, ABS-011, is in Phase 2b testing. Because the product is not yet approved for sale, the buyer rarely pays large billion amounts up-front. The risk that the product fails in the final tests is still present. Previous financing as a benchmark: Abscint raised a financing round of 3 million euros in 2023 to cover the Phase 2 studies. A young biotech company at this stage is typically acquired for a value 10 to 20 times greater than their latest capital raising. Typical deal structure: In this type of medical acquisition, Curium will likely only pay a smaller portion in cash here and now (e.g., 10-20 million euros). The rest of the amount will only be paid out if ABS-011 achieves success in the Phase 3 tests and is finally approved by the authorities.
- ·3 päivää sittenIt seems that we are gradually staying at this level, or what are people's impressions?Yes, it should be around this level. With current market cap. of approx. 700 mill I can quite easily imagine it quickly coming back to around 20 - 22 kr. Per Share.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt